AN AGRESULTS INITIATIVE
IMPLEMENTED BY GALVMED
AN AGRESULTS INITIATIVE
IMPLEMENTED BY GALVMED
Inviting applicants to enter the Brucellosis Vaccine Prize, Peter Jeffries outlines the benefits for commercial and academic organisations joining forces to collaborate on the US $30m competition.
Peter Jeffries summarises the Brucellosis Vaccine Prize, discussing the need for a new vaccine and the criteria for entry, as the US $30m competition enters its second phase.
If you have read July’s International Animal Health Journal, you will have seen Professor Javier Guitián from the Royal Veterinary College (RVC) explain that successful control of brucellosis in developed...
Are you a potential Solver seeking help with vaccine registration, manufacture, R&D or commercialization? Or do you work for an organization that is able to offer expertise, facilities or capabilities...
As first announced in July 2017, we are delighted to report on the award of the first Brucellosis Vaccine Prize competition prizes, with three organizations each receiving Milestone 1 Payments...
July 6th: Today is World Zoonoses Day – a date that has particular relevance in light of the global Brucellosis Vaccine Prize, a US $30 million prize competition inviting vaccine...
Brucellosis is a highly contagious zoonotic disease, which requires a One Health approach to address. Approximately 500,000 new human cases are reported annually, and the effects can be devastating.
Animal health innovators encouraged to collaborate on vaccine innovation
Vaccine development initiative remains open for entries to proof-of-concept stage
Awards to biotechnology, governmental and academic organisations across the world
GALVmed media inquiries
Beatrice Ouma
Senior Communications Manager | Global Alliance for Livestock Veterinary Medicines - GALVmed
Tel: +254 (0) 703700732
Email: [email protected]
AgResults media inquiries
Parasto Hamed Hamidi
AgResults Secretariat | Deloitte Consulting
Email: [email protected]
